Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

eas of pediatric infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at www.medimmune.com.

Forward Looking Statements

This announcement may contain, in addition to historical information, certain forward-looking statements regarding motavizumab, an investigational MAb, which involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in MedImmune's filings with the U.S. Securities and Exchange Commission. The company is developing motavizumab for potential future marketing. There can be no assurance that such development efforts will succeed, that motavizumab will receive required regulatory approval or that, even if such regulatory approval is received, that motavizumab would ultimately achieve commercial success.

Notice to Investors and Stockholders of MedImmune

This release is neither an offer to purchase nor a solicitation of an offer to sell shares of MedImmune. MedImmune stockholders are urged to read the relevant tender offer documents from AstraZeneca PLC which have been filed on May 3, 2007 because they will contain important information that stockholders should consider before making any decision regarding tendering their shares. AstraZeneca has filed tender offer materials with the U.S. Securities and Exchange Commission, and MedImmune has also filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. The tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement contain important informat
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis ... affordable laser tattoo removal experience with the advanced Astanza Duality laser ... high quality cosmetic services with cutting edge medical technology and offering ... California has seen a dramatic increase in the presence ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... , SAN FRANCISCO, Sept. 23 ... demonstrate that the company,s Combo Bio-engineered Sirolimus Eluting Stent (Combo ... eluting stent and the XIENCE(TM) V everolimus eluting stent. ... tomography (OCT) data out to 28 days show that the ...
... BERLIN, September 23 , ... Data,Which Highlight Benefits of Adding capecitabine to epirubicin and docetaxel,in ... the ABCSG-24 study presented today at the joint 15th ECCO ... to anthracycline- and taxane-containing regimens prior to surgery,(neoadjuvant therapy) completely ...
Cached Medicine Technology:Pre-clinical Data Show OrbusNeich's Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies 2Pre-clinical Data Show OrbusNeich's Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies 3Capecitabine Added to Standard Treatment Given Before Surgery Helps to Eradicate Tumours in Patients With Early Breast Cancer 2Capecitabine Added to Standard Treatment Given Before Surgery Helps to Eradicate Tumours in Patients With Early Breast Cancer 3Capecitabine Added to Standard Treatment Given Before Surgery Helps to Eradicate Tumours in Patients With Early Breast Cancer 4Capecitabine Added to Standard Treatment Given Before Surgery Helps to Eradicate Tumours in Patients With Early Breast Cancer 5
(Date:4/24/2014)... spectrum disorders (ASD), resides in genes that are part ... the Icahn School of Medicine at Mount Sinai, who ... the United States and throughout the world. The ... in Autism Spectrum Disorders," was first published online in ... April 24. , ASD affects about one percent ...
(Date:4/24/2014)... at UT Southwestern Medical Center previously discovered that the ... adult heart lacks this ability. New research by the ... its incredible regenerative capability in adulthood, and the answer ... It is well-known that a major function of the ... But at the same time, oxygen is a highly ...
(Date:4/24/2014)... during and after colorectal surgery cut hospital stays by ... who led a study of the approach at Duke ... easier on patients before surgery, doing away with the ... After surgery, patients are encouraged to eat and move ... , Among findings published in the May 2014 issue ...
(Date:4/24/2014)... and the relevance of palliation in advanced cancer ... controlled trials (RCTs). This is the result of ... and Efficiency in Health Care (IQWiG), which has ... with external experts, IQWiG analysed studies on four ... melanoma, and pancreatic cancer. For this purpose, the ...
(Date:4/24/2014)... first in the world to discover a gene mutation ... , Ameloblastoma is an odontogenic tumour with a high ... found in the posterior of the lower jaw. Ameoloblastomas ... in the jaws as well as loss of several ... for surgery and the recurrence of ameloblastoma, but finding ...
Breaking Medicine News(10 mins):Health News:Genetic alterations in shared biological pathways as major risk factor for ASD 2Health News:Oxygen diminishes the heart's ability to regenerate, researchers discover 2Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3
... , ANNAPOLIS, Md., July 27 ... biodefense company developing medical countermeasures against biological and chemical threats, ... issuance of 2-year, 10% unsecured senior convertible notes ("Notes") and ... approximately $19.3 million. , , In connection ...
... , , ... How can hospitals build sustainable physician alignment? While hospitals ... few physician-relationship management programs demonstrate value. A new "thought ... Ensuring the Stability and Vitality of Today,s Hospitals," illustrates ...
... , FRANKLIN, Mass., July 27 ... focused on innovative cardiac and vascular medical device-based technologies, today ... fluid balancing capabilities provided by RenalGuard(R) from the Canadian Intellectual ... company,s first patent for RenalGuard in Canada. , , ...
... reveals more about how information is processed, stored in the ... read her name, your Oprah neuron will probably rev up. ... neurons in the brain,s hippocampus activate when people recognize a ... distorted or presented in less than perfect fashion. , "Different ...
... MINNEAPOLIS, July 27 Premier Visiting Nurse, part ... entered into a business relationship with Cardiocom (R) ... chronic illness. Cardiocom, the Experts in Telehealth(SM), is ... of award-winning telehealth solutions. , , ...
... , , BOSTON, July 27 ... and information management solutions, today announced a new contract with Booth ... use the AMICAS ONE Suite(TM) as its end-to-end radiology software solution, ... care. , , (Logo: ...
Cached Medicine News:Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 2Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 3Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 4Health News:Proper Physician-Relationship Management Ensures Hospital Stability and Vitality 2Health News:Canada Grants PLC Systems First Patent for RenalGuard(R) 2Health News:Famous Names Get Single Neurons Fired Up 2Health News:Premier Visiting Nurse Selects Cardiocom Telehealth Technology 2Health News:Booth Radiology Extends and Elevates Partnership With AMICAS 2Health News:Booth Radiology Extends and Elevates Partnership With AMICAS 3
Fine angled tips ideal for grasping delicate capsule. Angled 12 mm shafts with iris stop allows ease of movement in the anterior chamber. Flat handle with dull finish. Manufactured in titanium....
Gently curved shaft with 2 mm platform ideal for performing capsulorhexis through a tunnel incision. Flat handle with dull finish....
Fine angled 12 mm shafts and iris stop. Round handle for fingertip rotational control. Dull finish....
Gently curved jaws with fine angled sharp tips for puncture and grasping the capsule. Round handle is excellent for precise finger tip control. Made in titanium....
Medicine Products: